

1 **Manuscript title:**

2 Relative expression of pro-inflammatory molecules in COVID-19 patients manifested disease
3 severities

4 **Running head:** Expression of pro-inflammatory molecules in COVID-19

5 **Authors:** Shireen Nigar ^{1#}, SM Tanjil Shah ^{2,3#}, Md. Ali Ahasan Setu ³, Sourav Dutta Dip ³,
6 Habiba Ibnat ³, M Touhidul Islam ⁴, Selina Akter ³, Iqbal Kabir Jahid ^{3,5**}, and M Anwar
7 Hossain ^{2,5,6**}

8
9 ¹Department of Nutrition and Food Technology, Jashore University of Science and Technology,
10 Jashore-7408, Bangladesh

11 ²Department of Microbiology, University of Dhaka, Dhaka-1000, Bangladesh

12 ³ Department of Microbiology, Jashore University of Science and Technology, Jashore-7408,
13 Bangladesh

14 ⁴ Consultant, Department of Cardiology, 250 Bedded General Hospital, Jashore

15 ⁵ Genome Center, Jashore University of Science and Technology, Jashore-7408, Bangladesh

16 ⁶ Vice-Chancellor, Jashore University of Science and Technology, Jashore-7408, Bangladesh

17 ****Corresponding author:**

18 Iqbal Kabir Jahid, Head of the Department of Microbiology, Jashore University of Science and
19 Technology, Jashore, Bangladesh. Phone: +8801709818178, Email: ikjahid_mb@just.edu.bd

20

21 M Anwar Hossain, Director, Genome Center, Jahore University of Science and Technology,
22 Jahore, Bangladesh. Vice-Chancellor, Jashore University of Science and Technology, Jashore-
23 7408, Bangladesh. Phone: +8801715363753, Email: hossaina@du.ac.bd

24 [#]These authors contributed equally to this study.

25

26 Institution where the work has been performed:

27 Jashore University of Science and Technology

28

29

30

31

32

33

34

35

36 **Abstract**

37 Aggressive immune response, due to over-expressed pro-inflammatory molecules, had been
38 characterized in COVID-19 patients. Some of those mediators have a dual and opposite role on
39 immune-systems to play behind differential disease severities. We investigated the expression of
40 some cytokines and chemokines in COVID-19 patients in Bangladesh. We diagnosed the
41 patients by detecting SARS-CoV-2 RNA in nasal swab samples by the real-time RT-PCR
42 method. Thirty adult patients were preselected based on their disease severities and grouped into
43 mild, moderate, and severe cases. Nine healthy volunteers participated in this study as control.
44 Relative expression of nine cytokines/chemokine in total leukocytes was semi-quantified in
45 SYBRgreen-based qRT-PCR. We performed statistical tests on transformed log data using SPSS
46 24.0. At the onset of symptoms (day-1), ACE2 ($P < 0.05$) and IL-6 ($P > 0.05$) were up-regulated
47 in all COVID-19 groups, although expression levels did not significantly correlate with disease
48 severities. However, expression of IL-6, MCP-1, MIP-1 α , TNF- α , RANTES, and ACE2, on day-
49 14, were positively correlated with disease severities. Relative viral load at day-1 showed no
50 significant correlation with cytokine expression but had a significant positive correlation with
51 RANTES and ACE2 expression on day-14 ($P < 0.05$). Male patients had a higher level of IL-6
52 than female patients on day-1 ($P < 0.05$). All COVID-19 patients showed up-regulated cytokines
53 and chemokines on the day-14 compared to day-1 except TNF- α . Female patients had higher
54 expression of ACE2 and IL-12 on day-14. Up-regulated cytokines/chemokines at the
55 convalescent stage, especially IL-6, may target anti-cytokine therapy in post-COVID-19 patients'
56 management.

57

58 **Keywords:** COVID-19, pro-inflammatory molecules, cytokines, chemokines, relative expression

59 **Introduction**

60 A novel coronavirus SARS-CoV-2 was identified in Wuhan, China, in December 2019 and has
61 lead to over 127 million cases and 2.79 million death worldwide as of March 31, 2021 ^[1].
62 However, surprisingly in Bangladesh, these days recorded 0.61 million confirmed cases and only
63 9046 deaths ^[1]. COVID-19 related deaths are significantly lower in countries with lower quality
64 of life ^[2]. Although most SARS-CoV-2 patients demonstrate mild or moderate symptoms, it
65 could also lead to excessive, ineffective and exaggerated immune responses called cytokine
66 release syndrome (CRS). The clinical response shows acute respiratory distress syndrome
67 (ARDS), multiple organ failure, and ultimately death ^[3]. Several authors reported the role of
68 cytokines and chemokines as a double-edged sword. Higher levels of chemokines (such as MCP-
69 1, MIP-1 α , MIP-1 β , RANTES, IP-10, and CCL3) and cytokines (such as IL-6, IL-8, IL-1b,
70 TNF- α , IFN γ , and GCSF, GMCSF) have reported for COVID-19 patients ^[3-6]. Several authors
71 have been reviewed the importance and function of these chemokines and cytokines ^[7-9] and
72 demonstrated the role of IL-6, TNF- α , IL-10, and IL-8 for disease severity.

73 The SARS-CoV-2 virus uses novel Metallo-carboxyl peptidase angiotensin receptor 2 (ACE2) to
74 enter its human host cell ^[10, 11]. In spite of acting as the viral receptor, ACE2 protects against
75 lung injury by degrading vasoconstrictive and proapoptotic protein ^[12]. ACE2 expressed higher
76 in severe patients than mild and moderate ^[13]. The authors also found upregulation of several
77 interferons, cytokines, and immune-related genes for severe patients compared with mild and
78 moderate patients. Biological sex variation influenced the severity of COVID-19 cases ^[14] as
79 reported in various studies; men are more likely to get severe forms of COVID-19 ^[15-17].

80 Investigations will identify therapeutic strategies with anti-cytokine targeting overactive pro-
81 inflammatory cytokines (TNF- α and IL-6). But the correct time for administrating anti-cytokine
82 therapies needs to be recognized for personalized treatment of COVID-19 patients. Furthermore,
83 the questions remained unanswered about the reasons for reduced severity and mortality in
84 developing countries like Bangladesh, except for dissimilarity in cytokine/chemokine expression
85 with recently reported data. We aimed to explore the relationships between disease severity and
86 relative cytokine expression levels, the effect of biological sex in clinical presentation or viral
87 load at the nasopharynx swap of COVID-19 patients.

88

89 **Materials & Methods**

90 **Ethical permission and Sample collection:**

91 The Ethical Review Committee of the Jashore University of Science and Technology approved
92 this study (ERC no: ERC/FBST/JUST/2020-49). A total of 30 symptomatic COVID-19 patients
93 were preselected, and patients were categorized into mild cases (n=10), moderate cases (n=10),
94 and severe cases (n=10) of COVID-19 according to the World Health Organization Guidelines
95 for Diagnosis and Treatment of COVID-19 infection ^[18]. We grouped patients with fever and
96 slight upper respiratory tract symptoms as mild cases; patients with shortness of breathing,
97 constant pain, or pressure in the chest as moderate cases; and patients with respiratory failure
98 requiring intensive care units (ICU) as severe COVID-19 cases. We informed individual
99 participants (COVID-19 patients) or their family members about the study protocol and took
100 verbal consent. The demographic information of all participants enlisted in Table 1. Ten healthy
101 individuals (gave their consent and participated in this study) were primarily selected, who were
102 free from recent respiratory diseases, acute or chronic infectious diseases, and had no co-
103 morbidities. They maintained home-quarantine from the beginning of the COVID-19 outbreak in
104 Bangladesh and tested negative for recent SARS-CoV-2 infection by using All Check COVID-
105 19 IgG/IgM antibody assay (CALTH Inc., Republic of Korea). We exclude a sample from one
106 volunteer in the final study due to the appearance of antibodies against SARS-CoV-2. All
107 participants were BCG vaccinated within one month of birth (identified by the skin scar/mark on
108 the left upper arm and their verbal confirmation). We have interviewed patients or their family
109 members to collect demographic data and clinical history from all qualified participants. From
110 hereafter, we refer to the healthy control as HC, mild COVID-19 cases as MIC, moderate
111 COVID-19 cases as MOC, and severe COVID-19 cases as SC.

112 **Quantification of SARS-CoV-2 viral load:**

113 We performed detection of SARS-CoV-2 at the Genome Centre, Jashore University of Science
114 and Technology, Jashore, Bangladesh. We extracted viral RNA from a 10 μ L clinical specimen
115 (nasal swab and throat swab) within 12 h of specimen collection using QuickExtractTM RNA
116 extraction kit (Lucigen, Wisconsin, USA) following the manufacturer's instruction. Then, 10 μ L
117 of each viral RNA extract was amplified by one-step real-time quantitative reverse-transcriptase
118 polymerase chain reaction (qRT-PCR) using Novel Coronavirus Nucleic Acid Diagnostic Kit
119 (Sansure Biotech Inc., China). The kit detected *n-* and *orf1b* gene of SARS-CoV-2 and human
120 *RNase P* gene as an internal control. In this study, samples with Ct values for both *n-* and *orf1b*
121 genes of ≤ 35.0 considered positive, that of >35.0 retested, and of >40.0 considered negative. We
122 used equation $2^{-\Delta Ct}$ to estimate viral load, where $\Delta Ct = Ct_{\text{viral N gene}} - Ct_{\text{RNaseP}}$ ^[19]. We have
123 translated all the data as $\text{Log}_{10}(1+2^{-\Delta Ct})$.

124 **Estimating cytokine and chemokine expression levels by qRT-PCR:**

125 We collected approximately 4 to 5 ml of peripheral blood samples, within 24-hours (day 1) of
126 laboratory confirmation of SARS-CoV-2 in nasopharyngeal swabs, from thirty COVID-19
127 symptomatic and nine symptomatic patients. After 14 days, we collected blood samples from
128 twenty patients with MIC (n=10) and MOC (n=10) symptoms from their residence while
129 maintaining home quarantine. Three healthy volunteers (out of nine) tested SARS-CoV-2
130 positive during repeated sampling and let off from the study. So we had six samples from healthy
131 volunteers on day-14. We could not collect blood samples from participants of the severe
132 COVID-19 cases as they were either decreased after 14 days of initial sample collection or

133 admitted into the intensive care unit (ICU) from whom we could not be allowed to collect the
134 blood.

135 We extracted total mRNA from human leukocytes using 1 mL of whole blood from all study
136 participants using the SV total RNA isolation system (Promega, USA), as per the manufacturer's
137 instruction. According to the manufacturer's instruction, we prepared 20.0 μ L cDNA from 8.0
138 μ L of total mRNAs using the GoScriptTM Reverse transcription system (Promega, USA). We
139 diluted 20 μ L cDNA into a final volume of 100.0 μ L. We performed SYBRgreen intercalation
140 qRT-PCR to detect the expression level of two pro-inflammatory cytokines (TNF- α and IL-6),
141 two antiviral cytokines (IFN- γ and IL-12), four chemokines (MIP-1 α , RANTES, IP-10, and
142 MCP-1), and ACE2. We used the primer sequences to detect these cytokines and chemokines
143 from an earlier study^[20]. The qRT-PCR was performed in QuantStudioTM 3 (Applied
144 Biosystems, USA), using the following protocol: denaturation at 95 °C for 2 min followed by 40
145 cycles of 95 °C for 10 s, annealing for 30 s, and extension at 72 °C for 30 s. We analyzed the
146 melting curve to determine the assay's specificity (60-95 °C, 0.05°C/s). Annealing temperature
147 varied for different primer pairs (such as ACE2: 53 °C; IL-6: 45 °C; TNF- α : 60 °C; IP-10: 45 °C;
148 IFN- γ : 48 °C; MIP-1 α : 58 °C; RANTES: 48 °C; MCP-1: 52 °C; IL-12: 50.5 °C; and β -actin: 60
149 °C). We performed each experiment in triplicate and Ct values with <10% variance considered
150 for analyses only. In this essay, the human β -actin gene worked as the internal control. We
151 accessed mRNA expression by relative quantification and calculated fold expression change by
152 the 2^{-ddCt} method^[21].

153 **Statistical analysis:**

154 The distribution of the fold expression change of mRNAs was skewed, so we log-transformed
155 these data for further analyses. Results presented as median (interquartile range). Non-parametric
156 tests such as the Kruskal-Wallis test and Mann-Whitney U-Test were used to compare relative
157 cytokine expression levels among the different groups where applicable. Spearman's rank
158 correlation coefficient (r) analyzes the correlation between relative cytokine expression levels in
159 total lymphocytes and the close viral load. Spearman rank correlation analyses the association
160 between disease severity and cytokine expression levels. We performed statistical tests based on
161 transformed log data using SPSS 24.0 for Windows (SPSS, Inc., Chicago, IL, USA) and
162 GraphPad Prism 8.0 (GraphPad Software, USA) to construct all the figures logarithmic scales. If
163 the two-tailed P values were <0.05, the test results were considered significant.

164

165 **Result**

166 **Demographic and clinical characteristics of studied participants**

167 The demographic characteristics and clinical aspects of thirty COVID-19 patients and nine
168 healthy volunteers listed in Table 1. Mean(\pm SD) age of MIC, MOC, and SC groups were
169 estimated as 37.30(\pm 4.814), 40.20(\pm 4.69), and 58.40(\pm 3.361) years, respectively. HC groups'
170 mean age was 23.89(\pm 2.435) years. All MOC participants (n=10) and SC (n=10) suffered from
171 shortness of breathing, but only two MIC reported such difficulties. All SC had respiratory
172 failure and thus required ICU support. We recorded no death for mild and moderate groups but
173 one death reported during the study period in the SC group.

174 **Relative expression levels of cytokine and chemokine in studied participants**

175 Fig 1 represented the comparison between different cytokine and chemokine expression levels on
176 day-1 and day-14 among the study groups. Statistical analyses showed no significant difference
177 ($P > 0.05$) among the four groups for any cytokine or chemokine on day-1, except for ACE2. The
178 ACE2 expressed higher ($P < 0.05$) in the MIC group than HC group. The relative expression
179 level of IL-6 was numerically higher in all COVID-19 groups than in the healthy control group,
180 although this difference was non-significant ($P > 0.05$).

181 To obtain changes of different cytokine and chemokine expression levels on day-14. Compared
182 with the HC, the MIC group had increased ($P < 0.05$) expressions of IL-12 and IFN γ and non-
183 significant higher expression of IP-10 and MCP-1 at day-14. On the other hand, the MOC had
184 statistically higher ($P < 0.05$) expressions of ACE2, IL-12, MCP-1, TNF- α , MIP-1 α , IL-6,
185 RANTES, IP-10, and IFN- γ on day-14 compared to the HC. Compared with the MIC group, the

186 MOC had numerically higher IL-6 levels and significantly higher expression ($P < 0.05$) of
187 RANTES and ACE2.

188 **Correlation between disease severity and cytokine and chemokine expression level**

189 Spearman rank correlation analyses were performed to determine any correlations between
190 disease severity and expression levels of cytokine and chemokine in COVID-19 patients,
191 separately for both day-1 and day-14. Correlation coefficients (r) for all cytokine and chemokine
192 (both day-1 and day-14) are shown in Fig 2A. Statistical analyses revealed that the relative
193 expression levels of IL-6 ($r = 0.609$), TNF- α ($r = 0.741$), MIP-1 α ($r = 0.607$), MCP-1 ($r = 0.486$),
194 RANTES ($r = 0.623$) and ACE2 ($r = 0.845$) on day-14 were positively correlated ($P < 0.05$) with
195 disease severity (Fig 2B). However, no significant correlation between disease severity with any
196 cytokine and chemokine was observed on day-1. But expression levels of IL-12 ($r = 0.102$), TNF-
197 α ($r = 0.110$), IFN- γ ($r = 0.166$), IL-6 ($r = 0.295$), IP-10 ($r = 0.210$), and MIP-1 α ($r = 0.128$) were
198 weakly positively correlated with severity on day-1.

199 **Correlation between viral load and cytokine and chemokine expression level**

200 Spearman rank correlation analyses were also done to determine any correlations between
201 relative viral load and expression levels of cytokine and chemokine in COVID-19 patients.
202 Correlation coefficients (r) for all cytokine and chemokine (both day 1 and day 14) are shown in
203 Fig 3A. Expression levels of only TNF- α ($r = 0.4469$) had non-significant positive correlation (P
204 > 0.05) with relative viral load at the onset of disease. Whereas IL-6 ($r = -0.4182$), RANTES ($r =$
205 -0.2376), MIP-1 α ($r = -0.2078$), and MCP-1 ($r = -0.3111$) had non-significant weak negative
206 correlation with relative viral load on day 1. However after 14 days, expression levels of
207 RANTES ($r = 0.4860$) and ACE2 ($r = 0.6471$) had significant positive correlation ($P < 0.05$) with

208 the relative viral load (Fig 3B). Moreover, relative expression levels were non-significantly
209 positively correlated with viral load for IL-12 ($r = 0.3516$), TNF- α ($r = 0.4615$), IL-6 ($r =$
210 0.4895), and MIP-1 α ($r = 0.3538$).

211 **Effect of gender on relative cytokine expression levels in COVID-19 patients**

212 To explore any effect of sex on cytokine and chemokine expression levels, we analyzed
213 cytokine's relative expression levels of males and females on both day-1 and day-14 (Fig 4).
214 Irrespective of sex, all cytokine and chemokine were up-regulated on day-14 than day-1, except
215 for IL-6 and TNF- α . For male, IL-6 expression level was similar on both sampling times. TNF- α
216 showed no significant difference in any comparison. The relative expression level of ACE2 and
217 IL-12 were also identical in both gender on day-1. But both ACE2 and IL-12 were up-regulated
218 ($P < 0.05$) in females on day-14. Additionally, we did not observe a significant difference in the
219 relative expression level of IFN- γ , RANTES, and IP-10 in males and females on both days. On
220 the other hand, MCP-1 and MIP-1 α were up-regulated ($P < 0.05$) in females on day-1. But did
221 not found any sex discrimination for expression of MCP-1 and MIP-1 α on day-14. The relative
222 expression level of IL-6 was higher ($P < 0.05$) in males on day-1 but did not vary significantly (P
223 > 0.05) with genders on day-14.

224

225 **Discussion**

226 To our knowledge, this is the first study on cytokine/chemokine expression level in COVID-19
227 patients in Bangladesh. We observed up-regulation of ACE2 ($P < 0.05$) and IL-6 ($P > 0.05$) in
228 MIC cases compared with HC on day-1 (Fig 1). Many natural, common ways such as taking

229 Vitamin C, Metformin, Vitamin B3, and Vitamin D can up-regulate ACE2 receptor ^[22]. Here in
230 Bangladesh, doctors instructed COVID-19 patients to take Vitamin C and Vitamin B3 during
231 their illnesses, increasing ACE2 expression. Although the virus uses ACE2 to enter into its host
232 cell, up-regulation of the cellular ACE2 receptor would likely be anti-inflammatory and might
233 have contributed to reduced mortality in COVID-19 patients. Pro-inflammatory cytokines such
234 as IL-6, TNF- α , while up-regulated, trigger cytokine storms and ultimately lead to tissue damage
235 and organ failure ^[23]. Although we observed a slightly increased expression of IL-6, we didn't
236 observe TNF- α up-regulation at the onset of the disease (Fig 1). Like our study, normal TNF- α
237 levels were reported in COVID-19 patients by Wan et al. ^[24]. However, elevated TNF- α levels in
238 COVID-19 patients' sera were also reported recently ^[4, 25]. Recently some studies reported IL-6
239 as severity predictors of COVID-19 ^[26, 27]. In a meta-analysis including 1426 patients,
240 complicated COVID-19 patients had higher IL-6 expression levels (>3 times) compared with
241 other uncomplicated patients ^[28]. In our study, COVID-19 patients had no higher expression of
242 either IFN- γ or IL-12 than the HC group, which is indicative of the absence of elevated antiviral
243 immune response at the onset of disease symptoms. Surprisingly, none of the cytokines and
244 chemokines of ICU patients from the SC group shows significant differences compared with
245 others. Zhang et al ^[29] found that ICU patients in China had higher levels of IL-2R, IL-6, IL8,
246 IL10, and TNF- α compared with reference ranges of the normal man. In other studies from
247 Finland, ICU patients had higher levels of IL-6, C-reactive protein, and procalcitonin compared
248 with non-ICU patients ^[30]. Keddie et al ^[31] also noted similar findings. The authors demonstrated
249 that CRP, IL-6, IL-10, and LDH significantly correlated with ARDS and respiratory support. In
250 another study, Lev et al ^[32] also noted that IP-10 is associated with ICU patients and act as
251 potential biomarkers. The combination of IL-6*IL-10 serum levels has shown a predictor of ICU

252 patients^[33]. The less expression of most cytokines and chemokines might be probable reasons
253 for less mortality rate (1.5%) of severe COVID-19 patients in Bangladesh.

254 Moreover, in our study, the relative expression of cytokine and chemokines differs between 2
255 weeks. After 14 days, significant up-regulation of both antiviral cytokines (IFN- γ and IL-12)
256 occurs in MIC and MOC. Although the antiviral immune response was not present in COVID-19
257 patients on the onset of disease, the antiviral immune response accelerated in those patients after
258 14 days. This up-regulation indicates enhanced host immunity to eliminate viral pathogens.

259 Similar IL-12 up-regulation reported in both SARS-CoV^[34] and SARS-CoV-2 infected patients
260^[4, 35]. IL-12 has distinctive characteristics and has a vital role in positive and negative feedback
261^[36]. On day 14, pro-inflammatory cytokine IL-6 was significantly higher in MOC but not in MIC
262 cases. Whereas another pro-inflammatory cytokine, TNF α , was significantly up-regulated in all
263 COVID-19 patients than HC. These findings suggest that pro-inflammatory cytokines had direct
264 effects on the severity and complexity of COVID-19 disease. The anti-inflammatory cytokines
265 levels got up-regulated compared to pro-inflammatory cytokines after 14 days. So, it might result
266 in rapid recovery and reduced mortality in COVID-19 patients. On day-14, RANTES and ACE2
267 also up-regulated with the severity of COVID-19 disease. RANTES, a well-established chemo-
268 attractant, links innate and adaptive immune response. RANTES decreased significantly in
269 SARS-CoV-2 infected persons in a recent study, where MIP-1 α level was higher in ICU patients
270^[4].

271 We observed that the relative expression of some cytokines and chemokines varied among
272 COVID-19 cases. Based on the samples' data on day 1, we could not establish any significant
273 correlation between disease severity and relative cytokine expressions. But after 14 days,
274 estimated expression levels of IL-6, TNF- α , MIP-1 α , MCP-1, RANTES, and ACE2 correlated

275 with and differed significantly with COVID-19 severity groups (Fig 2). Several reviews
276 highlighted the importance of cytokines and chemokines and demonstrated IL-1, IL-6, IL-8, IL-
277 10, IL-2R, IL-18, MCP-1, and TNF- α for disease severity ^[8, 37, 38]. The cytokines and chemokines
278 regulate the CD4 + T, CD8 +T, monocytes, neutrophils, and macrophages. However, we
279 observed differences in the expressions between studies. Recent work by Qin et al ^[25] is also in
280 accord with our observation, where COVID-19 severity was associated with increased levels of
281 IL-6, IP-10, MCP-1, and MIP-1 α . Although Costela-Ruiz et al ^[7] reported elevated TNF- α and
282 its association with severity in COVID-19 patients, we didn't observe such differences. In
283 another study, even the samples from nasopharyngeal swabs revealed the higher expression of
284 IFN- γ and lowered expression of TGF- β 1 and RANTES in symptomatic patients compared with
285 negative patients ^[39]. But our studies demonstrated the higher expression of RANTES for MIC
286 and MOC compared with HC. At the onset of disease, the relative viral load had no significant
287 correlation with cytokines and chemokines' relative expression (Fig 3A). However, initial viral
288 load positively correlated with expression levels of IL-12, TNF- α , IL-6, RANTES, MIP-1 α , and
289 ACE-2, after 14 days. A higher level of IL-6 and RANTES decreased CD8+ T cell and virus ^[40].
290 The results from our study agreed with that study.

291 Although male tends to get more severe forms of COVID-19 diseases, we observed significant
292 gender variation only for IL-6, MIP-1 α , and MCP-1 on day 1 (Fig 4). Our observations of male
293 patients who had up-regulated IL-6 than female patients at the beginning of the disease agreed
294 with China's similar findings. The study reported a higher level of serum IL-6 male compared to
295 female. Increased expression of IL-6 on day-1 might result in severe COVID-19 diseases in
296 males. Interestingly both males and females had similar expression levels of pro-inflammatory
297 cytokines (TNF- α , IL-6) after 14 days. On day-14, female patients had significant up-regulation

298 of ACE2 and IL-12. In response to vaccinations, women induced a robust immune response ^[41].
299 In a previous study, estrogens lead to cytokine up-regulation in mice treated with coronavirus.
300 Estrogens had a protective role by suppressing the immune response's escalation phase ^[42]. As
301 women are expressing more ACE2, therefore, less severity and death rate has been attributed in
302 Bangladesh. A recent study showed that, compared with male patients, severe female patients
303 had a greater IgG production level in weeks of the COVID-19 disease onset ^[6]. The protective
304 role of IgG in female COVID-19 patients might be associated with the up-regulation of IL-12.

305 There were a few limitations along with the small sample size in our study. We could not collect
306 repeated blood samples after 14 days from severe patients admitted to ICU. We also estimated
307 the relative expression levels of cytokines and chemokines instead of serum cytokine levels.
308 However, live vaccines such as the bacillus Calmette- Guerin (BCG) are known to induce trained
309 immunity (enhanced innate immune response to subsequent infections). COVID-19 cases
310 reported being lower in countries with universal BCG vaccination programs (such as
311 Bangladesh, Nepal, Bhutan, Japan) compared to those without the programs (such as the USA,
312 Spain, Canada, Italy) ^[43]. We hypothesized that BCG vaccination might induce an immune
313 response and reduce SARS-CoV-2 viremia and the severity of COVID-19 infections ^[44], and
314 rapid recovery of SARS-CoV-2 infection in the country.

315 **Conclusion**

316 This study describes cytokine and chemokine expression among COVID-19 patients with
317 different disease severity in a developing country, Bangladesh. We found that IL-6 could be
318 targeted for anti-cytokine therapy here in Bangladesh. Although we could not prove any direct
319 effect of BCG vaccinations on reduced severity of COVID-19, our data provide cytokine

320 expression levels in BCG vaccinated COVID-19 patients. Knowledge of the underlying
321 mechanisms of differential expressions and associations of these cytokines with disease severity
322 could help target the choice of therapies.

323 **Acknowledgments**

324 This work was supported by a research grant (UGC/JUST/2020-21/20) from the University
325 Grant Commission, Bangladesh, through Jashore University of Science and Technology (JUST),
326 Jashore. We thank all volunteers and COVID-19 patients who actively participated in this study.
327 We also acknowledge the efforts of all doctors, nurses, health-care workers in fighting SARS-
328 CoV-2.

329 **Declaration of competing interest**

330 The authors declare no competing interest to this work.

331 **Authors' contribution statement**

332 Shireen Nigar conceived the idea; SM Tanjil Shah, Ali Ahsan Setu, Sourav Datta Dip, Habiba
333 Ibnat and Selina Akter performed the experiment; M Touhidul Islam collected and performed
334 initial processing of samples; SM Tanjil Shah and Iqbal Kabir Jahid performed statistical
335 analysis; Shireen Nigar and SM Tanjil Shah wrote the draft manuscript; Selina Akter, Iqbal
336 Kabir Jahid and M Anwar Hossain finalize the manuscript; Shireen Nigar, Iqbal Kabir Jahid and
337 M Anwar Hossain supervised the whole work and submitted the manuscript.

338

339

340 **References:**

- 341 1. Dong E, Du H and Gardner L, An interactive web-based dashboard to track COVID-19 in
342 real time. *Lancet Infect Dis.* 2020;**20**(5): 533-534.
- 343 2. Escobar LE, Molina-Cruz A and Barillas-Mury C, BCG vaccine protection from severe
344 coronavirus disease 2019 (COVID-19). *Proc Natl Acad Sci.* 2020;**117**(30): 17720-17726.
- 345 3. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS and Manson JJ, COVID-19:
346 consider cytokine storm syndromes and immunosuppression. *Lancet.* 2020;**395**(10229):
347 1033-1034.
- 348 4. Huang C, Wang Y, Li X, et al., Clinical features of patients infected with 2019 novel
349 coronavirus in Wuhan, China. *Lancet.* 2020;**395**(10223): 497-506.
- 350 5. Blanco-Melo D, Nilsson-Payant BE, Liu W-C, et al., Imbalanced host response to SARS-
351 CoV-2 drives development of COVID-19. *Cell.* 2020;**181**(5): 1036-1045. e9.
- 352 6. Zeng F, Dai C, Cai P, et al., A comparison study of SARS-CoV-2 IgG antibody
353 between male and female COVID-19 patients: a possible reason underlying different
354 outcome between sex. *J Med Virol.* 2020.
- 355 7. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C and Melguizo-Rodríguez
356 L, SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. *Cytokine Growth*
357 *Factor Rev.* 2020.
- 358 8. Mulchandani R, Lyngdoh T and Kakkar AK, Deciphering the COVID-19 cytokine
359 storm: Systematic review and meta-analysis. *Eur J Clin Invest.* 2021;**51**(1): e13429.
- 360 9. Mauvais-Jarvis F, Aging, male sex, obesity, and metabolic inflammation create the
361 perfect storm for COVID-19. *Diabetes.* 2020;**69**(9): 1857-1863.

- 362 10. Turner AJ, Tipnis SR, Guy JL, Rice GI and Hooper NM, ACEH/ACE2 is a novel
363 mammalian metallocarboxypeptidase and a homologue of angiotensin-converting
364 enzyme insensitive to ACE inhibitors. *Can J Physiol Pharmacol.* 2002;**80**(4): 346-353.
- 365 11. Li W, Moore MJ, Vasilieva N, et al., Angiotensin-converting enzyme 2 is a functional
366 receptor for the SARS coronavirus. *Nature.* 2003;**426**(6965): 450-454.
- 367 12. Gopallawa I and Uhal BD, Angiotensin-(1-7)/mas inhibits apoptosis in alveolar epithelial
368 cells through upregulation of MAP kinase phosphatase-2. *Am J Physiol Lung Cell Mol*
369 *Physiol.* 2016;**310**(3): L240-L248.
- 370 13. Jain R, Ramaswamy S, Harilal D, et al., Host transcriptomic profiling of COVID-19
371 patients with mild, moderate, and severe clinical outcomes. *Comput Struct Biotechnol J.*
372 2021;**19**: 153-160.
- 373 14. Wei X, Xiao Y-T, Wang J, et al., Sex differences in severity and mortality among
374 patients with COVID-19: evidence from pooled literature analysis and insights from
375 integrated bioinformatic analysis. *arXiv preprint arXiv:2003.13547*, 2020.
- 376 15. Yang X, Yu Y, Xu J, et al., Clinical course and outcomes of critically ill patients with
377 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
378 observational study. *Lancet Respir Med.* 2020;**8**(5).
- 379 16. Abate BB, Kassie AM, Kassaw MW, Aragie TG and Masresha SA, Sex difference in
380 coronavirus disease (COVID-19): a systematic review and meta-analysis. *BMJ open.*
381 2020;**10**(10): e040129.
- 382 17. Liu T, Balzano-Nogueira L, Lleo A and Conesa A, Transcriptional differences for
383 COVID-19 Disease Map genes between males and females indicate a different basal
384 immunophenotype relevant to the disease. *Genes.* 2020;**11**(12): 1447.

- 385 18. Jin Y-H, Cai L, Cheng Z-S, et al., A rapid advice guideline for the diagnosis and
386 treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard
387 version). *Mil Med Res.* 2020;**7**(1): 4.
- 388 19. Chi Y, Ge Y, Wu B, et al., Serum Cytokine and Chemokine Profile in Relation to the
389 Severity of Coronavirus Disease 2019 in China. *J Infect Dis.* 2020;**222**(5): 746-754.
- 390 20. Law HK, Cheung CY, Ng HY, et al., Chemokine up-regulation in sars-coronavirus-
391 infected, monocyte-derived human dendritic cells. *Blood.* 2005;**106**(7): 2366-2374.
- 392 21. Livak KJ and Schmittgen TD, Analysis of relative gene expression data using real-time
393 quantitative PCR and the 2- $\Delta\Delta$ CT method. *Methods.* 2001;**25**(4): 402-408.
- 394 22. McLachlan CS, The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention
395 and treatment of COVID-19 are distinctly different paradigms. *Clin Hypertens.*
396 2020;**26**(1): 1-3.
- 397 23. Tanaka T, Narazaki M and Kishimoto T, Immunotherapeutic implications of IL-6
398 blockade for cytokine storm. *Immunotherapy.* 2016;**8**(8): 959-970.
- 399 24. Wan S, Yi Q, Fan S, et al., Characteristics of lymphocyte subsets and cytokines in
400 peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia
401 (NCP). *MedRxiv*, 2020.
- 402 25. Qin C, Zhou L, Hu Z, et al., Dysregulation of immune response in patients with
403 coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* 2020;**71**(15): 762-768.
- 404 26. Han H, Ma Q, Li C, et al., Profiling serum cytokines in COVID-19 patients reveals IL-6
405 and IL-10 are disease severity predictors. *Emerg Microbes Infect.* 2020;**9**(1): 1123-1130.
- 406 27. Liu Y, Zhang C, Huang F, et al., Elevated plasma level of selective cytokines in COVID-
407 19 patients reflect viral load and lung injury. *Natl Sci Rev.* 2020.

- 408 28. Aziz M, Fatima R and Assaly R, Elevated interleukin-6 and severe COVID-19: A
409 meta-analysis. *J Med Virol.* 2020.
- 410 29. Zhang D, Zhou X, Yan S, et al., Correlation between cytokines and coagulation-related
411 parameters in patients with coronavirus disease 2019 admitted to ICU. *Clinica Chimica*
412 *Acta.* 2020;**510**: 47-53.
- 413 30. Broman N, Rantasärkkä K, Feuth T, et al., IL-6 and other biomarkers as predictors of
414 severity in COVID-19. *Ann Med.* 2020;1-5.
- 415 31. Keddie S, Ziff O, Chou MK, et al., Laboratory biomarkers associated with COVID-19
416 severity and management. *Clin Immunol.* 2020;**221**: 108614.
- 417 32. Lev S, Gottesman T, Sahaf Levin G, et al., Observational cohort study of IP-10's
418 potential as a biomarker to aid in inflammation regulation within a clinical decision
419 support protocol for patients with severe COVID-19. *Plos one.* 2021;**16**(1): e0245296.
- 420 33. Nagant C, Ponthieux F, Smet J, et al., A score combining early detection of cytokines
421 accurately predicts COVID-19 severity and intensive care unit transfer. *Int J Infect Dis.*
422 2020;**101**: 342-345.
- 423 34. Wong C, Lam C, Wu A, et al., Plasma inflammatory cytokines and chemokines in severe
424 acute respiratory syndrome. *Clin Exp Immunol.* 2004;**136**(1): 95-103.
- 425 35. Chen N, Zhou M, Dong X, et al., Epidemiological and clinical characteristics of 99 cases
426 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.*
427 2020;**395**(10223): 507-513.
- 428 36. Jones LL and Vignali DA, Molecular interactions within the IL-6/IL-12 cytokine/receptor
429 superfamily. *Immunol Res.* 2011;**51**(1): 5.

- 430 37. Noroozi R, Branicki W, Pyrc K, et al., Altered cytokine levels and immune responses in
431 patients with SARS-CoV-2 infection and related conditions. *Cytokine*. 2020;155:143.
- 432 38. Bindoli S, Felicetti M, Sfriso P and Doria A, The amount of cytokine-release defines
433 different shades of Sars-Cov2 infection. *Exp Biol Med*. 2020;**245**(11): 970-976.
- 434 39. Villalba MCM, Ramírez OV, Jiménez MM, et al., Interferon gamma, TGF- β 1 and
435 RANTES expression in upper airway samples from SARS-CoV-2 infected patients. *Clin*
436 *Immunol*. 2020;**220**: 108576.
- 437 40. Patterson BK, Seethamraju H, Dhody K, et al., Disruption of the CCL5/RANTES-CCR5
438 pathway restores immune homeostasis and reduces plasma viral load in critical COVID-
439 19. *MedRxiv*, 2020.
- 440 41. Lotter H and Altfeld M. Sex differences in immunity. in *Seminars in Immunopathology*.
441 2019. Springer.
- 442 42. Taghizadeh-Hesary F and Akbari H, The powerful immune system against powerful
443 COVID-19: A hypothesis. *Med Hypotheses*. 2020;109762.
- 444 43. Sharma AR, Batra G, Kumar M, et al., BCG as a game-changer to prevent the infection
445 and severity of COVID-19 pandemic. *Allergol Immunopathol*. 2020.
- 446 44. Curtis N, Sparrow A, Ghebreyesus TA and Netea MG, Considering BCG vaccination to
447 reduce the impact of COVID-19. *Lancet*. 2020;**395**(10236): 1545-1546.

448

449

450 **Figure legends**

451 **Figure 1: Relative expression levels of cytokine and chemokine in healthy control and**
452 **COVID-19 infected symptomatic patients (mild COVID-19 cases, moderate COVID-19**
453 **cases, and severe COVID-19 cases). ● = Healthy Control; ■ = Mild COVID-19 cases; ▲ =**
454 **Moderate COVID-19 cases; and ▼ = Severe COVID-19 cases. Each RT-PCR was done in**
455 **triplicate and data those vary <10% were taken for analyses. Because of this, number of samples**
456 **varies for different cytokine and chemokine. Data are expressed as median with interquartile**
457 **range (IQR). Separate analyses were performed for day 1 and day 14. For any cytokine, different**
458 **letters in different column indicates significant differences ($P < 0.05$). Abbreviations: NA, not**
459 **available (severe COVID-19 cases data on day 14); IL, interleukin; IFN, interferon; TNF, tumor**
460 **necrosis factor; RANTES, Regulated upon activation, normal T cell expressed and secreted; IP-**
461 **10, interferon-inducible protein of 10 kDa; MIP, macrophage inflammatory protein; MCP,**
462 **monocyte chemotactic protein; and ACE, angiotensin converting enzyme.**

463



464 **Figure 2: Correlation between disease severity and relative expression levels of cytokine**
465 **and chemokines.** (A). Spearman rank correlation analyses between disease severity and cytokine
466 expression levels were done, and correlation coefficient (r) values of IL-12, IFN- γ , TNF- α , IL-6,
467 RANTES, IP-10, MIP-1 α , MCP-1, and ACE2 on day 1 and day 14 are plotted. * P < 0.05, **P <
468 0.01, ***P < 0.001. (B). Correlation between disease severity and relative expression levels of
469 IL-6, TNF- α , RANTES, MIP-1 α , MCP-1, and ACE2 after 14 days are plotted. Here in the X
470 axis, 1= healthy volunteer, 2= mild COVID-19 cases, and 3= moderate COVID-19
471 cases. Abbreviations: IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES,
472 Regulated upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible
473 protein of 10 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic
474 protein; and ACE, angiotensin converting enzyme.

475

476

477 **Figure 3: Correlation between relative viral load and relative expression levels of cytokine**
478 **and chemokines in COVID-19 patients.** (A). Spearman rank correlation analyses between
479 relative viral load and cytokine expression levels were done, and correlation coefficient (r)
480 values of IL-12, IFN- γ , TNF- α , IL-6, RANTES, IP-10, MIP-1 α , MCP-1, and ACE2 on day 1 and
481 day 14 are plotted. * $P < 0.05$, ** $P < 0.01$. (B). Correlation between relative viral load and
482 expression levels of IL-12, TNF- α , IL-6, RANTES, MIP-1 α , and ACE2 after 14 days are plotted.
483 Abbreviations: IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES, Regulated
484 upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible protein of 10
485 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; and ACE,
486 angiotensin converting enzyme.

487

488 **Figure 4: Relative expression levels of cytokine and chemokine in male and female COVID-**
489 **19 patients.** Here,  = male and  = female COVID-19 infected patients. Each RT-PCR was
490 done in triplicate and data those vary <10% were taken for analyses. Because of this number of
491 samples varies for different cytokine and chemokine. Data are expressed as median with
492 interquartile range (IQR). Separate analyses were performed for day 1 and day 14. For any
493 cytokine, different letters in different column indicates significant differences ($P < 0.05$).
494 Abbreviations: IL, interleukin; IFN, interferon; TNF, tumor necrosis factor; RANTES, Regulated
495 upon activation, normal T cell expressed and secreted; IP-10, interferon-inducible protein of 10
496 kDa; MIP, macrophage inflammatory protein; MCP, monocyte chemotactic protein; and ACE,
497 angiotensin converting enzyme.

498

499

500

501

502

503

504

505










506

507

Table 1. Demographic and clinical characteristics of studied participants.


Characteristics	HC (n=9)	MIC (n=10)	MOC (n=10)	SC (n=10)
Men	5 (55.55%)	6 (60%)	8 (80%)	6 (60%)
Women	4 (44.45%)	4 (40%)	2 (20%)	4 (40%)
Age [mean(±SD)] years	23.89(±2.435)	37.30(±4.814)	40.20(±4.69)	58.40(±3.36)
Fever (temperature >37 °C)	0	8 (80%)	10 (100%)	9 (90%)
Cough	0	4 (40%)	8 (80%)	8 (80%)
Headache	0	5 (50%)	6 (60%)	6 (60%)
Malaise	0	2 (20%)	10 (100%)	7 (70%)
Myalgia	0	2 (20%)	5 (50%)	3 (30%)
Loss of taste or odor	0	0	6 (60%)	4 (40%)
Shortness of breathing	0	2 (20%)	7 (70%)	10 (100%)
Constant pain or pressure in chest	0	3 (30%)	5 (50%)	5 (50%)
SPO ₂ at rest ≤ 94%	0	0	0	6 (60%)
Respiratory failure requiring intensive care unit treatment	0	0	0	10 (100%)
Diabetes	0	0	0	4 (40%)
Hypertension	0	0	1 (10%)	6 (60%)







Abbreviations: HC; Healthy control, MIC; mild COVID-19 cases, MOC; moderate COVID-19 cases, SC; severe COVID-19 cases.




medRxiv preprint doi: <https://doi.org/10.1101/2021.04.01.21254770>; this version posted April 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






A



B**IL-6****TNF- α** **RANTES****MIP-1 α** **MCP-1****ACE2**

A



B**IL-12****TNF- α** **IL-6****RANTES****MIP-1 α** **ACE2**